IP Library Granted Patent US 9,017,729
Granted Patent B2
US 9,017,729 · App. 14/311,464 · Granted Apr 28, 2015

Method and composition for hyperthermally treating cells

Inventor: Gholam A. Peyman (Sun City, AZ)
A61K47/48569A61K41/0052A61K45/06A61B6/00A61B6/032A61B6/037A61N2/002A61N2/004A61N2/02A61N5/025A61B8/0841A61N5/1001A61B3/13A61N7/02A61B5/0095A61B5/01A61B5/4836A61K49/227B82Y99/00A61N5/1017A61F9/0079A61F2009/00863G01R33/4808A61K47/48861A61K47/48884
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,729
App. No.
14/311,464
Granted
Apr 28, 2015
Kind
B2
Abstract

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

Claims (20)

1. A method providing immunotherapy in combination with thermal therapy to a target site in a patient in need thereof, the method comprising

(i) providing thermotherapy by

administering to a patient a composition comprising a targeting agent and/or antitumor-antibody-labeled nanoparticle wherein the nanoparticle forms a targeting agent and/or antibody labeled nanoparticle-cell complex at a tumor site,

exposing the patient to an energy source wherein the nanoparticles respond by expanding thus generating an acoustic signal,

measuring the acoustic signal and relating the measured signal to a temperature of the nanoparticle-cell complex, and

controlling the temperature of the nanoparticle-cell complex from about 39° C. to about 58° C. based on the acoustic signal to hyperthermally damage or kill cells in the tumor; and

(ii) providing immunotherapy by at least one of

providing to the patient an immunotherapy agent associated with the nanoparticles,

providing to the patient an immunotherapy agent not associated with the nanoparticles,

providing a therapeutic concentration of autologous leukocytes to the patient; the immunotherapy to enhance a patient's immune response.

2. The method of claim 1 where thermotherapy is performed in the absence of a contrast agent.

3. The method of claim 1 where thermotherapy is performed substantially simultaneously with immune therapy.

4. The method of claim 1 where thermotherapy is performed prior to immune therapy.

5. The method of claim 1 where thermotherapy is performed subsequent to immune therapy.

6. The method of claim 1 where the immunotherapy reduces at least one effect of immunosuppression, and where the thermotherapy supplements chemotherapy and/or radiation therapy.

7. The method of claim 1 further comprising evaluating at least one marker to assess a therapy effect.

8. The method of claim 1 where the nanoparticle is associated with a member of specific binding pair.

9. The method of claim 8 where the specific binding pair is selected from the group consisting of streptavidin-biotin, cellular receptor-agonist or antagonist, enzyme-substrate, antibody-antigen, and combinations thereof.

10. The method of claim 1 where the nanoparticle is associated with a virus.

11. The method of claim 10 where the virus is selected from the group consisting of a modified virus, a tumoricidal virus, an adenovirus, and combinations thereof.

Continuity (13)
Continuation In Part 13915282 · Jun 11, 2013
Continuation In Part 13665458 · Oct 31, 2012
Continuation In Part 13610503 · Sep 11, 2012
Continuation In Part 13527005 · Jun 19, 2012
Continuation In Part 13455237 · Apr 25, 2012
Continuation In Part 13361786 · Jan 30, 2012
Continuation In Part 13307916 · Nov 30, 2011
Continuation In Part 13189606 · Jul 25, 2011
Continuation In Part 13149209 · May 31, 2011
Continuation In Part 12478029 · Jun 4, 2009
Continuation In Part 11485352 · Jul 13, 2006
Division 10073863 · Feb 14, 2002
Related Publication 20140303590A1 · Oct 9, 2014